1. Scrip
  2. >>Business
  3. >>Financing

Idogen Running Out Of Survival Options

Swedish Firm Seeking Reverse Merger Solution

 
• By Kevin Grogan

With very little cash left in the bank, Idogen is weighing up its options including a reverse merger or liquidation.

Padlock
Idogen faces closure if reverse merger efforts fail • Source: Shutterstock

The future of Idogen AB hangs in the balance with the Swedish firm's critical financial situation leaving its lead clinical-stage development program IDO 8 for hemophilia in limbo.

Idogen's announcement on 28 April that its "work with capitalization has not yet produced the desired result" is quite an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.